MarketPulse

Eli Lilly

2 articles
BenzingaBenzinga··Vandana Singh

Eli Lilly's Eczema Drug Clears Phase 3 Pediatric Hurdle, Eyes Label Expansion

Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.
LLYFDA approvalPhase 3 trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Pharma Dominance: Why $LLY Attracts Long-Term Wealth Builders

$LLY dominates diabetes and weight management markets while diversifying into oncology and AI, positioning itself as a compelling long-term wealth-building investment within diversified portfolios.
NVDALLYlong-term investingdividend reinvestment